Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

113.90 -2.17 (-1.87%)
Streaming Delayed Price Updated: 9:41 AM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
News headline image
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies
From Merck & Co., Inc.
Via Business Wire
R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments
Palm Beach, FL – January 27, 2022 – FinancialNewsMedia.com News Commentary – According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018,... 
Via FinancialNewsMedia
Topics Death Intellectual Property
News headline image
Accelerating Global Access
SOURCE: Merck & Co., Inc. 
Via 3BL Media
News headline image
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces Second-Quarter 2022 Dividend
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Provides U.S. and Japan Regulatory Update for Gefapixant
From Merck & Co., Inc.
Via Business Wire
Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer
Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to... 
Via FinancialNewsMedia
Topics Death
News headline image
Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine
From Merck & Co., Inc.
Via Business Wire
News headline image
Frank Clyburn to Leave Merck
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck and Ridgeback Announce Supply Agreement With UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
SOURCE: Merck & Co., Inc. 
Via 3BL Media
News headline image
Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities
SOURCE: Merck & Co., Inc. 
Via 3BL Media
News headline image
Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck and Ridgeback's Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19
SOURCE: Merck & Co., Inc. 
Via 3BL Media
News headline image
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine
SOURCE: Merck & Co., Inc. 
Via 3BL Media
News headline image
Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine
From Merck & Co., Inc.
Via Business Wire
News headline image
ADDING and REPLACING European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
From Merck & Co., Inc.
Via Business Wire
News headline image
European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Issues $1 Billion Inaugural Sustainability Bond
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Issues $1 Billion Inaugural Sustainability Bond
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Topics Bonds Emissions Intellectual Property
Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 10, 2021 – USA News Group – Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel... 
Via FinancialNewsMedia
Topics Artificial Intelligence
< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.